Analyzing OneMedNet (NASDAQ:ONMD) and Charles River Laboratories International (NYSE:CRL)

OneMedNet (NASDAQ:ONMD) and Charles River Laboratories International (NYSE:CRL) are both computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Earnings & Valuation

This table compares OneMedNet and Charles River Laboratories International’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OneMedNet	$1.02 million	14.00	-$23.20 million	($0.19)	-3.15
Charles River Laboratories International	$4.13 billion	2.91	$474.62 million	$9.21	25.35

Charles River Laboratories International has higher revenue and earnings than OneMedNet. OneMedNet is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares OneMedNet and Charles River Laboratories International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OneMedNet	N/A	N/A	-116.74%
Charles River Laboratories International	11.49%	16.53%	7.02%

Risk & Volatility

OneMedNet has a beta of -0.46, meaning that its stock price is 146% less volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.

Insider and Institutional Ownership

1.0% of OneMedNet shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 45.7% of OneMedNet shares are owned by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for OneMedNet and Charles River Laboratories International, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OneMedNet	0	0	0	0	N/A
Charles River Laboratories International	0	4	7	0	2.64

Charles River Laboratories International has a consensus target price of $253.23, indicating a potential upside of 8.46%. Given Charles River Laboratories International’s higher possible upside, analysts plainly believe Charles River Laboratories International is more favorable than OneMedNet.

Summary

Charles River Laboratories International beats OneMedNet on 11 of the 13 factors compared between the two stocks.

About OneMedNet

OneMedNet Corporation provides clinical imaging solutions. It offers iRWD, a solution that utilizes AI to securely de-identify, search, and curate imaging data for its partner network consisting of medical and academic research institutions to generate progression in stages of medical research, discovery and diagnostics that span the field of life sciences. The company is based in Eden Prairie, Minnesota.

About Charles River Laboratories International

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.